TARA
Protara Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.33
+0.43%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$2.35
From 52W high−69.18%
Volume1.18M
Market cap$137.69M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$2.35
From 52W high
−69.18%
Volume
1.18M
Market cap
$137.69M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.8x
P/E (TTM)
—
RSI (14)
24.7
MomentumView details →
1D Return
+0.43%
YTD Return
−55.44%
SummaryUpdated Jun 1, 2026
Protara Therapeutics, Inc. (NASDAQ:TARA) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in New York, New York. Originally incorporated as ArTara Therapeutics, Inc., the company changed its name to Protara Therapeutics in May 2020. The company focuses on identifying and advancing transformative therapies for the treatment of cancer and rare diseases, with a particular emphasis on developing innovative cell therapies and substrate replacement treatments for underserved patient populations.
Similar companies
Latest newsMore news →
Protara Therapeutics, Inc. completed enrollment of 24 patients in the Phase 2b open-label dose-confirmation phase of its THRIVE-3 trial evaluating IV choline chloride in patients with intestinal failure dependent on parenteral support.4d agoProtara Therapeutics reported a net loss of $21.7 million for Q2 2026, with research and development expenses of $17.0 million and general and administrative expenses of $6.4 million.70d ago